Iridex competitors

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX). David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

George Babich has more than 30 years of financial, business operations and strategic planning experience in public and private companies focused in technology, retail, consumer products, manufacturing and service sectors. Mr. Babich is an advisor to CEOs on financial, operating and leadership issues as well as business strategy. He has advised private equity on acquisition opportunities and has facilitated business relationships amongst clients and potential partner organizations.

Seasoned executive, with proven leadership in all business aspect, results-driven, savvy in the global environment, dynamic, entrepreneurial, analytic and strategic thinker. Experienced in P&L responsibility, sales & marketing, turn-around and M&A. Product knowledge spans: medical devices, pharmaceuticals, consumer electronics goods, telecommunication, enterprise SW solutions, consumer goods and pharmaceuticals. Industry experience: consumer electronics goods, telecommunication, and enterprise SW solutions.

David Andrew Fischel (born 1 April 1958) is a British businessman. He was formerly the chief executive of Intu Properties Group plc, a British shopping centre management and development company between 2001 and 2019.